Multiplexed Gene Expression as a Characterization of Bioactivity for Interferon Beta (IFN-β) Biosimilar Candidates: Impact of Innate Immune Response Modulating Impurities (IIRMIs)-Reference-Cited by-同舟云学术

Multiplexed Gene Expression as a Characterization of Bioactivity for Interferon Beta (IFN-β) Biosimilar Candidates: Impact of Innate Immune Response Modulating Impurities (IIRMIs)

Published:2019-02-08 Issue:2 Volume:21 Page:
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Mufarrege Eduardo F.,Haile Lydia A.,Etcheverrigaray Marina,Verthelyi Daniela I.

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1208/s12248-019-0300-7.pdf

Reference30 articles.

1. Kasper LH, Reder AT. Immunomodulatory activity of interferon-beta. Annals of Clinical and Translational Neurology. 2014;1(8):622–31.

2. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. 2002;58(8 Suppl 4):S3–9.

3. Rudick RA, Goelz SE. Beta-interferon for multiple sclerosis. Exp Cell Res. 2011;317(9):1301–11.

4. Meager A, Dolman C, Dilger P, Bird C, Giovannoni G, Schellekens H, et al. An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products. J Interf Cytokine Res. 2011;31(4):383–92.

5. Stroncek DF, Jin P, Wang E, Jett B. Potency analysis of cellular therapies: the emerging role of molecular assays. J Transl Med. 2007;5(1):24.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of IFNβ-1a versions with reduced immunogenicity and full in vitro biological activity for the treatment of multiple sclerosis;Clinical Immunology;2023-12

2. Immunogenicity Study of Biosimilar Candidates;Drug Development and Safety [Working Title];2023-02-27

3. Type I interferon signaling facilitates resolution of acute liver injury by priming macrophage polarization;Cellular & Molecular Immunology;2023-01-04

4. Detection of innate immune response modulating impurities (IIRMI) in therapeutic peptides and proteins: Impact of excipients;Frontiers in Immunology;2022-09-06

5. Innate Immunity Modulating Impurities and the Immunotoxicity of Nanobiotechnology-Based Drug Products;Molecules;2021-12-01